Drug Profile
Research programme: solid tumour therapeutics - DCPrime/Glycotope
Alternative Names: DCOne® Cell Vaccine; DCP-002; DCP-00XLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator DCPrime
- Class Antibodies; Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Solid-tumours in Netherlands (Parenteral)
- 21 Dec 2020 DCPrime has been acquired by Immunicum
- 21 Sep 2020 DCprime and Glycotope expands their licensing agreement to combine cancer vaccine and antibody platform for Solid tumours